Find a clinical trial


If you have questions about clinical trials or want help finding the right one for you, contact our:

Patient Engagement Center Phone: 844-552-2734

This is a preliminary search of all open and enrolling clinical trials across our regions and affiliate organizations that have sponsors' permission to publish to this website.

Please use the filtering options in the right column to refine your search. Otherwise ALL open and enrolling clinical trials will display below.

« Previous 12 Next »
Viewing Page 1 of 2 | Showing Results 1 - 5 of 7

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Hospitalized Patients with COVID-19

This is a multicenter, randomized, double-blind, placebo-controlled study of IC14, an antibody to CD14, in reducing the severity of respiratory...

Shane O'Mahony, M.D.
  • Swedish Medical Center

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for COVID-19

Key Inclusion Criteria:*Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) positive as determined by Polymerase Chain Reaction (PCR) or...

Jason Goldman, M.D.
  • Swedish Medical Center

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Inclusion Criteria:Subject is male or female at least 18 years of ageFemale subject must be postmenopausal, permanently sterilized or willing to...

Philip Mease, M.D.
  • Swedish Medical Center


Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No CriteriaInclusion...

Jason Tarpley, M.D.
  • California Research
  • Providence Little Company of Mary Torrance
  • Providence Los Angeles Research Center

MILED, the trial of early, low dose, long term (2 yr) sirolimus to determine if early intervention can prevent decline in patients with mild LAM

Inclusion Criteria:• Female, age 18 or over• Signed and dated informed consent Diagnosis of LAM as determined by compatible lung CT and:1) biopsy...

George Pappas, M.D.
  • Swedish Medical Center
« Previous 12 Next »
Viewing Page 1 of 2 | Showing Results 1 - 5 of 7